Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses telogen effluvium, emphasizing the importance of understanding its natural progression and highlights the need for a detailed patient evaluation but provides no new clinical results.

Tofacitinib might be used to treat hair loss.

This study of alopecia areata patients found that a 10 mg twice-daily dose of oral tofacitinib led to significant hair regrowth, suggesting it may be beneficial for treatment.

In this study of foxes and jackals in Ilam province, Iran, 19.35% of foxes and 17.85% of jackals were found to be infested with ectoparasites, mainly Ctenocephalides canis.

Teledermatology reduces unnecessary in-person visits and improves care.

This letter provides historical insights into the origin of the term "androgenetic alopecia," highlighting its use by Dr. Orentreich in the late 1950s based on his autograft studies.

This study observed that ethylenthiourea's lethality increases with dose accumulation and ethanol co-administration, while impaired liver function and various adverse effects were noted in long-term treated rats.

A specific gene mutation (Y449H in K10) was found in a patient with severe skin disorder.

This study introduced a viscoelastic dry electrode that successfully reduces motion artifacts in EP monitoring on hairy skin, maintaining stable performance for up to 48 days.

This abstract introduces the concept of follicular units (FUs) in the human scalp but presents no new research findings.

This study suggests that epitestosterone may play a role in regulating androgen-dependent processes like prostate growth and body hair distribution by counteracting testosterone's actions.

This article addresses the definition, diagnosis, and characteristics of telogen effluvium, a form of diffuse hair loss, but reports no new clinical results.

This retrospective study found that oral tofacitinib significantly reduced the severity of alopecia areata in children, achieving over a 50% reduction in hair loss severity, though relapse occurred during treatment tapering, and mild adverse effects were noted.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

In this retrospective study, combining TACE with Donafenib showed promising results as a first-line treatment for Chinese patients with unresectable hepatocellular carcinoma, yielding a median progression-free survival of 12.8 months and a one-year overall survival rate of 87.5%, along with a favorable safety profile.

This article highlights the significant hair transplant results achieved with the potentially obsolete FUT technique and includes varied expert opinions on its efficacy, but it reports no new clinical findings.

This study found that a solid shampoo containing 15% tin leaf extract (Ficus carica L.) and 1% vitamin E exhibited strong antioxidant activity, with a 53.43% inhibition of free radicals in hair and scalp, suggesting potential for reducing hair loss and premature aging.

This study found that low-level laser therapy effectively reduced relapse rates, while functional appliances did not; combining them offered no additional benefits.

This article reports a notification from Dr. Greg Williams to the FUE Research Committee, but it provides no new research findings.

In this study, tofacitinib treatment significantly reduced hair loss on the head and body, as well as nail involvement, in patients with alopecia areata over 18 months, with minimal side effects reported.

This review discusses telogen effluvium, emphasizing its identifiable causes and treatment options, and reports no new clinical results.

This study found that a green tea extract gel was stable across various temperatures, did not cause eye irritation, and significantly increased eyelash growth compared to a placebo after two months of use in human volunteers.

In this study, LED therapy for eyebrow loss in older females with frontal fibrosing alopecia significantly increased eyebrow hair count after 10 treatments and maintained improvement at 6 months, indicating it could be a promising and well-tolerated treatment option.